INHIBIKASE THERAPEUTICS ($IKT) posted quarterly earnings results for Q1 2026 on Tuesday, May 12th. The company reported earnings of -$0.10 per share, beating estimates of -$0.11 by $0.01. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $IKT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
INHIBIKASE THERAPEUTICS Insider Trading Activity
INHIBIKASE THERAPEUTICS insiders have traded $IKT stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $IKT stock by insiders over the last 6 months:
- CAPITAL LIFE SCIENCES PULSE FUND II, L.P. SANDS purchased 2,068,965 shares for an estimated $2,999,999
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
INHIBIKASE THERAPEUTICS Hedge Fund Activity
We have seen 55 institutional investors add shares of INHIBIKASE THERAPEUTICS stock to their portfolio, and 16 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SIREN, L.L.C. added 5,850,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $11,992,499
- SOLEUS CAPITAL MANAGEMENT, L.P. added 4,550,000 shares (+71.9%) to their portfolio in Q4 2025, for an estimated $9,327,500
- SATURN V CAPITAL MANAGEMENT LP added 3,856,799 shares (+inf%) to their portfolio in Q4 2025, for an estimated $7,906,437
- BLACKSTONE INC. added 3,300,000 shares (+125.1%) to their portfolio in Q4 2025, for an estimated $6,764,999
- ADAR1 CAPITAL MANAGEMENT, LLC added 2,816,346 shares (+53.7%) to their portfolio in Q4 2025, for an estimated $5,773,509
- FAIRMOUNT FUNDS MANAGEMENT LLC added 2,500,000 shares (+40.8%) to their portfolio in Q4 2025, for an estimated $5,125,000
- SANDS CAPITAL ALTERNATIVES, LLC added 2,068,965 shares (+18.9%) to their portfolio in Q4 2025, for an estimated $4,241,378
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
INHIBIKASE THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $IKT in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Buy" rating on 01/21/2026
To track analyst ratings and price targets for INHIBIKASE THERAPEUTICS, check out Quiver Quantitative's $IKT forecast page.
INHIBIKASE THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $IKT recently. We have seen 4 analysts offer price targets for $IKT in the last 6 months, with a median target of $5.0.
Here are some recent targets:
- Aydin Huseynov from Ladenburg Thalmann set a target price of $4.0 on 03/04/2026
- Jason Zemansky from B of A Securities set a target price of $6.0 on 01/21/2026
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $8.0 on 12/26/2025
- Olivia Brayer from Cantor Fitzgerald set a target price of $4.0 on 12/11/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
